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The role of T lymphocytes in pathogenesis of chronic inflammatory airway diseases e asthma
and chronic obstructive pulmonary disease (COPD) has been emphasized in recent years: the
importance of ab T-cells (CD8þ and CD4þ) has been widely described. A substantial fraction
of gd T-cells is a composite part of pulmonary T lymphocytes. Specific localisation of gd T-cells
in epithelium/mucosa-rich tissues implies their potential role in local inflammatory immune
response, which occurs in chronic inflammatory airway diseases.
An investigation was made of the T-lymphocyte subsets in induced sputum (IS), in bronchoal-
veolar lavage (BAL) and in peripheral blood from 20 patients with COPD (stages IIeIII; GOLD),
18 patients with asthma (persistent mild to moderate; GINA) and 14 healthy subjects. Relation-
ship of gd T-cells with lung function and smoking history was analysed. COPD patients had
significantly higher numbers of CD8þT-cells in the airways of smokers compared to ex-
smokers in the COPD group. A significant positive correlation was found between CD8þT-
cells and pack-years of smoking. Differently, the COPD patients had significantly lower relative
and absolute numbers of gd T-cells in IS and in BAL compared to those from asthma or healthy
subjects. The quantity of gd T-cells negatively correlated with forced expiratory volume in 1 s
and smoking (pack-years) only in COPD group.munology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009, Kaunas,
yahoo.co.uk, daivaurboniene@one.lt (D. Urboniene).
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414 D. Urboniene et al.Our findings indicate a different local inflammatory response in COPD patients and in asth-
matic groups. The reduced amount of gd T-cells in IS and in BAL from COPD patients raises the
hypothesis about their important role in pathogenesis of COPD.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Chronic airway inflammation is a core pathogenetic
component in chronic obstructive lung diseases such as
chronic obstructive pulmonary disease (COPD) and
asthma.1e3 The role of ab T-cells (CD8þ or CD4þ) in the
pathogenesis of both diseases has been emphasized in
recent years.4e8
The recent studies show that the gd T-cells can comprise
up to 50% of the T cells within epithelium or mucosa-rich
tissues and less than 10% in peripheral blood.9e12 The
specific localization and abundance of these cells suggests
that these cells might be markedly implicated in epithelial/
mucosal immunity.13,14 Experimental studies with the lung
tissue provide substantial data about unique role of
pulmonary intraepithelial gd T-cells in tissue repair and
protection of the lung against respiratory infections or
other damaging agents (e.g. environmental stimuli) of
a different origin.13,15 It was shown that, in the absence of
gd T-cells, an onset of lung injury is more rapid, epithelial
injury is more severe and the clearance of damaged
epithelial cells is defective.13,15 gd T-cells are also
described as important modulators in airway hyper-
responsiveness as they can produce Th-2 type cytokines.16
There are a limited number of studies on pulmonary gd
T-cells in chronic obstructive inflammatory lung diseases.
Increased numbers of gd T-cells were reported in the
bronchoalveolar lavage (BAL) from patients with allergic
asthma8 and in induced sputum (IS) from patients with
acute exacerbation of asthma.17 Recent studies described
blunted response of BAL gd T-cells from COPD patients:
enhanced expression of these cells was mainly associated
with current smoking.18,19 Nonetheless, knowledge about
the potential role of gd T-cells at airway surfaces in COPD
and asthma is still quite limited.
The present study was undertaken to investigate
T-lymphocyte subsets and particularly gd T-cells in patients
with COPD and asthma, to evaluate their role in the path-
ogenesis of those diseases. For this purpose, an assessment
was made of the relative and absolute counts of
T-lymphocyte subsets in different tissue compartments (IS,
BAL, peripheral blood (PB)) from patients with COPD and
with asthma, and then this was compared to healthy
subjects. There was also the aim to analyze possible rela-
tions of T-lymphocyte subsets with the lung function and
with cigarette smoking history.
Methods
Study population
The present study was part of the study Pathogenetic
Mechanisms of Chronic Obstructive Pulmonary Disease(CAPTA) involved 52 outpatients (aged 30e80 years) from
the Department of Pulmonology and Immunology, Hospital
of Lithuanian University of Health Sciences Kaunas Clinics.
Three groups comprised the study population: COPD
patients (n Z 20), asthma patients (n Z 18) and healthy
subjects (nZ 14). COPD was diagnosed according to Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria.6 Patients included in the COPD group had clinically
stable COPD (II and III stages) and had a smoking history of
more than 10 pack-years. None of them had a deficiency of
the alfa-1 antitrypsin (patients were screened by PIZ 210
ELISA kit; Wieslab; Lund, Sweden). The asthma group con-
sisted of patients with persistent, mild to moderate asthma
that was diagnosed and classified according to the Global
Initiative for Asthma (GINA).20 Healthy subjects, without
known airway diseases and with normal lung function, were
recruited to serve as a control group. None of the study
participants had any symptoms of respiratory tract infec-
tion or disease exacerbation for at least 4 weeks before the
study, nor had used inhaled or systemic corticosteroids and
long-acting bronchodilators for at least 8 weeks before the
study. The study protocol was approved by the Kaunas
Regional Ethics Committee for Biomedical Research, Clin-
ical Trials gov NCT01378039. Written informed consent was
obtained from all the participants.
Lung function testing
Treatment with long-acting bronchodilators was withheld
for at least 48 h and, with short-acting bronchodilators, for
at least 8 h prior to lung function testing. Lung function was
tested by spirometry using the Custo Vit M pneumo-
tachometric spirometer (Custo Med; Munich, Germany)
with subjects in the sitting position. A record was made of
the highest value of forced expiratory volume in 1 s (FEV1)
and the highest value of the forced vital capacity (FVC)
from at least two, technically satisfactory maneuvers
differing by less than 5%. The predicted values were char-
acterized according to Quanjer et al.21
Sputum induction and processing
Sputum induction was performed as previously
described.22,23 An ultrasonic nebulizer (Ultraneb 2000;
DeVilbiss Health Care; Somerset, PA, USA) was used for the
sputum induction. Before sputum induction, all patients
inhaled salbutamol (200 mg) via a standard metered dose
inhaler. Baseline FEV1 was measured. This measurement
was repeated following each 5 min period of salbutamol
inhalation of nebulized hypertonic saline solution (incre-
mental concentrations e 3%, 4% and 5%). The procedure
was stopped whenever FEV1 fell by >10% following the
saline inhalation or fell by >20% at any time during the
Table 1 Monoclonal antibodies used in the study.
Specificity-fluorochrome Clone Isotype
Ms IgG2a-FITC/IgG1-PE
isotype control
X40 Ms IgG1, k;
X39 Ms IgG2a
CD45-PerCP 2D1 Ms IgG1, k
CD3-FITC HIT3a Ms IgG2a
TCR-gd-PE B1 Ms IgG1, k
CD4-PE RPA-T4 Ms IgG1,k
CD8-FITC RPA-T8 Ms IgG1,k
Ms, mouse; Ig, immunoglobulin; FITC, fluorescein iso-
thiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll
a protein; k, kappa light chains.
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(to preserve the viability of the cells) and processed
immediately.
Solid sputum material was separated from saliva before
processing, as previously described.23,24 In brief the
selected sputum was weighed and treated with 0.1%
dithiothreitol (DTT; SigmaeAldrich; Germany) at a ratio of
4 mL to 1 g sputum. The mixture was incubated at room
temperature for 15 min on a rolling mixer. The same volume
of phosphate-buffered saline (PBS; SigmaeAldrich;
Germany) was added to the homogenized sample. The cell
suspension was separated using a cell strainer with a 40 mm
nylon filter (Becton Dickinson; NJ, USA). The filtrate was
centrifuged at 400  g for 10 min at 4 C to pellet cells.
The total cell count (TCC) was calculated using the
Neubauer haemocytometer (Heinz Herenz Medizinalbedarf;
Hamburg, Germany), and viability was evaluated by the
trypan blue exclusion method. The cell suspension was
adjusted to 1.0  106 cells/mL. Part of the cell suspension
was used to know the quantity of the lymphocyte pop-
ulation. Cytospins were prepared using a Cytospin 2 cyto-
centrifuge (Shandon Scientific; Sewickley, PA, USA). The
slides were stained with May-Grunwald-Giemsa stain
(Merck; Darmstadt, Germany). Differential cell counts were
performed by an observer blind to the clinical character-
istics of the subjects. At least two slides were used for
counting the cell composition of 400 cells excluding the
squamous epithelial cells. Lymphocyte counts were
expressed as a percentage of total cells and as absolute
values (cells/mL).
Bronchoscopy and bronchoalveolar lavage
processing
Bronchoscopy was performed one week after the sputum
induction procedure using the Olympus BF-1 T200 flexible
fibreoptic bronchoscope (Olympus Optical; Tokyo, Japan)
as per the previously described protocol.23 In brief, the
subjects were pretreated with atropine and, under local
anesthesia, with Lidocaine (Grindex; Riga, Latvia) with
a bronchoscope that was wedged to a subsegmental bron-
chus. BAL was performed from the right middle lobe using
7  20 mL (total 140 mL) aliquots of sterile saline solution
(0.9% NaCl) warmed to 37 C. The BAL was gently aspirated
immediately after the infusion had been completed; then it
was immediately transferred to 50 mL polypropylene tubes
on ice (to retain the viability of the cells) and processed
immediately.
BAL processing and differential cell counts were per-
formed as described above for IS processing, with the major
exception that no DTT was used for homogenization.
Peripheral blood collection and processing
PB was drawn into BD Vacutainer K3EDTA tubes (BD;
Franklin Lakes, NJ, USA) by peripheral venipuncture
according to the standard procedure. Part of the PB sample
was used for the absolute and differential enumeration of
the lymphocyte population with the ADVIA 120 automated
hematology analyzer (Bayer HealthCare; Tarrytown, NY,
USA).Evaluation of T-lymphocyte subsets
The remaining parts of the IS and BAL cell suspensions were
processed for an analysis of T-lymphocyte subsets by flow
cytometry within 1 h after sample collection and the PB
samples e within 2 h. IS and BAL cells were washed and
resuspended in PBS containing 0.1% sodium azide (BD
Biosciences; San Jose, CA, USA) which was adjusted to
2  106 cells/mL.
For each test, aliquots of cells were directly stained
with monoclonal antibodies (mAb) by incubation at 4 C
for 45 min in the dark. The mAbs that were used (BD
Biosciences Pharmingen; San Diego, CA, USA) are listed in
Table 1. Optimal dilutions were established in preliminary
experiments. Red cells in PB samples were lysed with FACS
lysing solution (BD Biosciences; San Jose, CA, USA). The
cells of all samples were washed in PBS and resuspended
in CellFix (BD Biosciences; San Jose, CA, USA); subse-
quently they were analysed using a FACS Canto flow
cytometer (BD Immunocytometry Systems; San Jose, CA,
USA). Up to 70,000 total events were collected per
sample. The lymphocyte population was selected on the
basis of granularity/complexity (side scatter e SSC) and
the CD45 level of expression (Fig. 1). Matched isotype
control mAbs were used to determine the borderline
between the stained and unstained cells. The number of
positive cells with CD3, CD4, CD8 and TCR-gd expression
was analyzed as a percentage of the cells in the lympho-
cyte gate. The absolute count of cells was calculated
using the percentage of CD or TCR positive T-cells
measured by flow cytometry, and the absolute count of
lymphocytes.
Statistical analysis
Statistical analysis was performed using standard statistics
software (SPSS Version 17.0 for Windows, Microsoft Inc.,
USA). The KruskaleWallis test for multiple independent
samples was used to evaluate differences between the
groups, and Mann Whitney U test e to compare groups
individually. Bonferroni adjustment has been employed for
comparisons between multiple groups. Correlations
between variables were estimated by Spearman’s rank
correlation test. Statistical significance was assumed at
p < 0.05. Bonferroni adjusted p values were used where
appropriate.
Figure 1 Representative example of flow cytometric analysis
with a gate encompassing the lymphocyte population. The gate
R1 is set on a CD45 vs. a side scatter (SSC) dot plot in (a) IS
sample, (b) BAL sample and (c) PB sample.
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Characteristics of study subjects
Characteristics of the study subjects are presented in
Table 2. The mean age did not differ significantly between
the study groups. The COPD patients had smoked more
pack-years compared to the asthmatics and healthy
subjects. The lung function parameters of COPD patients
were significantly lower compared to healthy subjects and
compared to asthma patients. Lung function parameters of
asthma patients were significantly lower compared to
healthy subjects with the exception of the FEV1/FVC ratio.
T-lymphocyte subsets in induced sputum
Sputum induction was successfully performed on all partic-
ipants. Total cell count and the viability of cells in IS did not
differ significantly between any of the studied groups
(Table 3). The relative numbers of the lymphocyte pop-
ulation in COPD patients were significantly lower than those
in the asthma or healthy groups, but the absolute numbers
did not differ between any of the studied groups (Table 3).
However, patients with COPD had significantly lower relative
and absolute numbers of IS gd T-cells compared to asthmatic
patients and healthy subjects (Fig. 2a, Table 3). But the
percentage of IS CD8þ T-cells were significantly higher in
patients with COPD compared to asthmatic patients and to
healthy subjects (52  5.1% vs. 31  2.9% and 32  2.7%,Table 2 Characteristics of study subjects.
Parameter Healthy,
n Z 14
COPD,
n Z 20
Asthma,
n Z 18
Male/female (n) 8/6 11/9 7/11
Age (years) 59  9 63  7 58  10
Smokers/ex-
smokers/never
smokers (n)
5/5/4 10/10/0 5/4/9
Smoking
(pack-years)
9  3 30  15*yy 14  9
Smokers 9  9 30  13 14  8
Ex-smokers 10  9 29  14 14  9
FEV1 (L) 3.4  0.6 1.7  0.7**y 2.8  0.8#
FEV1
(% predicted)
109.2 
14.3
55.1 
16.5**y
88.5 
13.9#
FVC (L) 3.9  0.8 3.3  0.8 3.5  0.7
FEV1/FVC 88.8 
12.1
52.1 
13.1*y
79.0 
11.5
FEV1/FVC
(% predicted)
107.5 
10.1
65.2 
10.5*y
101.1 
9.9
COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity.
Data are presented as mean  SD unless otherwise noted. Data
were analyzed using the KruskaleWallis test followed by the
ManneWhitney U test with Bonferroni correction. Significant
difference indicators e Bonferroni-adjusted p values: *p < 0.05;
**p < 0.01 COPD patients vs. healthy subjects; yp < 0.05;
yyp < 0.01 COPD patients vs. asthma patients; #p < 0.05 asthma
patients vs. healthy subjects.
Table 3 Numbers of lymphocytes and gd T-cells in IS, BAL and PB from studied subjects.
Variable Healthy n Z 14 COPD n Z 20 Asthma n Z 18
IS
TTC (cells/mL) 2.95  106 (1.35e11.90)
 106
2.60  106 (1.00e5.25)
 106
3.20  106 (2.50e5.65)
 106
Viability (%) 79.80 (65.90e92.00) 77.60 (57.25e92.20) 78.70 (59.00e90.55)
Lymph. (%) 6.00 (3.50e11.35) 4.50 (2.80e6.45)y 7.60 (5.43e9.80)
Lymph. (cells/mL) 151.19  103 (144.19e419.14)
 103
119.17  103 (69.67e244.12)
 103
148.86  103 (101.51e364.54)
 103
gd T-cells (cells/mL) 4.09  103 (2.64e7.97)
 103
0.33  103 (0.16e0.71)
 103***yyy
4.66  103 (1.89e7.55)
 103
CD3þ T cells (cells/mL) 138.18  103 (65.01e200.00)
 103
104.17  103 (60.61190.17)
 103
134.10  103 (69.11220.21)
 103
CD4þ T cells (cells/mL) 67.62  103 (41.52e100.22)
 103
44.08  103 (20.62e60.76)
 103
92.38  103 (60.60e190.37)
 103y#
CD8þ T cells (cells/mL) 47.04  103 (26.71e55.98)
 103
58.01  103 (40.61e81.14)
 103*y
43.19  103 (21.22e60.50)
 103
BAL
TTC (cells/mL) 0.23  106 (0.10e0.25)
 106
0.18  106 (0.10e0.25)
 106
0.21  106 (0.16e0.26)
 106
Viability (%) 88.90 (76.55e97.00) 84.40 (70.05e90.10) 85.75 (70.00e96.63)
Lymph. (%) 25.05 (19.83e32.48) 25.50 (11.40e31.25) 28.00 (20.80e37.55)
Lymph. (cells/mL) 51.20  103 (21.28e86.30)
 103
46.80
 103 (34.75e94.20)  103
48.25  103 (36.15e91.58)
 103
gd T-cells (cells/mL) 1.69  103 (1.37e3.89)
 103
0.29  103 (0.16  0.78)
 103***yyy
2.52  103 (1.52e4.17)
 103
CD3þ T cells (cells/mL) 45.20  103 (32.27e85.31)
 103
42.78  103 (36.55e88.29)
 103
44.22  103 (32.11e87.52)
 103
CD4þ T cells (cells/mL) 20.01  103 (11.11e41.01)
 103
18.11  103 (11.41e40.03)
 103y
26.54  103 (15.92e51.02)
 103#
CD8þ T cells (cells/mL) 16.83  103 (10.41e32.05)
 103
25.38  103 (16.41e51.55)
 103*y
17.85  103 (10.42e31.22)
 103
PB
Lymph. (%) 29.70 (26.50e37.20) 22.60 (17.85e29.40) 30.45 (23.68e34.80)
Lymph. (cells/mL) 2.05  109 (1.53e2.10)
 109
1.70  109 (1.45e2.05)
 109
1.90  109 (1.30e2.20)
 109
gd T-cells (cells/mL) 80.00  106 (65.50e87.50)
 106
63.50  106 (57.25e74.25)
 106
74.00  106 (48.50e94.75)
 106
CD3þ T cells (cells/mL) 1.87  106 (1.63e2.00)
 106
1.58  106 (1.23e1.65)
 106
1.90  106 (1.30e2.20)
 106
CD4þ T cells (cells/mL) 0.92  106 (0.84e1.10)
 106
0.78  106 (0.55e0.97)
 106
0.85  106 (0.72e0.97)
 106
CD8þ T cells (cells/mL) 0.59  106 (0.43e0.67)
 106
0.49  106 (0.21e0.77)
 106
0.55  106 (0.41e0.68)
 106
COPD, chronic obstructive pulmonary disease; IS, induced sputum; BAL, bronchoalveolar lavage; PB, peripheral blood; TTC, total cell
count; lymph, lymphocytes.
Data are presented as a median (25the75th percentile).
Data were analyzed using the KruskaleWallis test followed by the ManneWhitney U test with Bonferroni correction. Significant
difference indicators e Bonferroni-adjusted p values: *p < 0.05; ***p < 0.001 COPD patients vs. healthy subjects; yp < 0.05; yyyp < 0.001
COPD patients vs. asthma patients; #p < 0.05 asthma vs. healthy group.
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true for IS CD8þ T-cells absolute numbers (Table 3).
There were no significant differences either in the
numbers of IS gd T-cells or numbers of IS CD8þ T-cells
between asthmatic patients and healthy subjects, butsignificantly higher numbers of IS CD4þ T-cells were in
asthmatic patients compared to COPD and healthy subjects
(62  4.5% vs. 45  3.8% and 46  4.9%, respectively;
Bonferroni adjusted p < 0.01). Absolute numbers are pre-
sented in Table 3.
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Figure 2 The percentage of gd T-cells in (a) IS, (b) BAL and
(c) PB from COPD patients, asthmatics and healthy subjects.
Horizontal lines represent median values. Significant differ-
ence indicators: ***p < 0.001; NS e not significant.
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Adequate BAL was obtained from all study subjects. The
total cell count, viability, and quantity of the lymphocyte
population in BAL did not differ significantly between COPD
and asthmatic patients or between COPD and healthy
subjects (Table 3).While analyzing the results obtained from BAL, the same
tendency of lymphocyte distribution was observed as in the
IS samples. The relative numbers of gd T-cells in BAL, as
well as the absolute numbers, were significantly lower
(Fig. 2b, Table 3) and CD8þ T-cells in BAL were signifi-
cantly higher in COPD patients compared to asthmatic
patients and to healthy subjects, but did not differ
significantly between asthmatic patients and healthy
subjects (53  2.3% vs. 37  1.7% and 33  1.9%, respec-
tively; Bonferroni adjusted p < 0.01). Absolute numbers
are presented in Table 3. The higher numbers of CD4þ T-
cells in BAL were observed in asthmatic patients compared
to COPD patients and healthy subjects (55  3.9% vs.
41  2.8% and 44  2.3%, respectively; Bonferroni adjusted
p < 0.017). Absolute numbers are presented in Table 3.
T-lymphocyte subsets in peripheral blood
There were no significant differences in the numbers of PB
lymphocyte subsets between any of the studied groups. The
same was true for the absolute numbers of PB lymphocyte
subsets (Table 3).
T-lymphocyte subsets and lung function
In COPD patients, the relative numbers of IS gd T-cells posi-
tively correlated with FEV1 (Fig. 3a). There were no signifi-
cant correlations either in the asthma group or in healthy
subjects. The relative numbers of IS gd T-cells did not
correlate with FEV1/FVC in COPD, asthma or healthy groups.
The similar positive correlation was found between the
numbers of BAL gd T-cells and FEV1 in COPD patients
(Fig. 3b), and no correlation was found in the asthma or
healthy groups. BAL gd T-cells, similarly like IS gd T-cells,
did not correlate with FEV1/FVC in any of the three studied
groups. No associations between the percentage of PB gd T-
cells and FEV1 in the COPD group were obtained (Fig. 3c).
The same was true for the asthma and healthy groups. There
were no correlations between the relative numbers of PB gd
T-cells and FEV1/FVC in any of the three studied groups.
Contrarily, in COPD patients, IS CD8þT-cells and BAL
CD8þT-cells showed negative correlations with FEV1
(r Z 0.653, p Z 0.012; r Z 0.502, p Z 0.011, respec-
tively). PB CD8þT-cells did not correlate with FEV1
(rZ 0.250, pZ 0.299). IS CD8þT-cells and BAL CD8þT-cells
did not show any correlations in asthmatic patients and
healthy subjects too.
In the asthma group, negative correlations between
CD4þT-cells from airways (IS and BAL) and FEV1 were
observed (r Z 0.532, p Z 0.010; r Z 0.601, p < 0.001,
respectively), but no correlations were found between
these cells from PB and FEV1 (r Z 0.222, p Z 0.283).
No correlations were found between CD4þT-cells either
from airways or from PB and FEV1/FVC. CD3þT-cells did not
show any correlations with lung function parameters in any
of the three studied groups.
T-lymphocyte subsets and smoking history
The findings of differences in the numbers of lymphocyte
subsets from airways prompted an evaluation of
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Figure 3 Relationship between gd T-cells and FEV1 in COPD
patients. (a) The percentage of IS gd T-cells positively corre-
lates with FEV1 (rZ 0.654, p Z 0.002). (b) The percentage of
BAL gd T-cells positively correlates with FEV1 (r Z 0.721,
p < 0.001). (c) The percentage of PB gd T-cells does not
correlate with FEV1 (r Z 0.252, p Z 0.283).
Distribution of gd and other T-lymphocyte subsets in COPD and asthma 419lymphocyte subsets according to patients’ smoking status.
There were no differences in age, lung function parameters
between the subgroups of smokers and ex-smokers within
every studied group. Smoking history (pack-years) did not
differ significantly between smokers and ex-smokers within
the same study group (Table 2).The relative and absolute numbers of CD8þT-cells were
higher in IS and BAL from COPD smokers compared to COPD
ex-smokers (IS: 57  4.7% vs. 47  4.9%; 58  103 cells/
mL  103 vs. 54  103 cells/mL; respectively; p < 0.05 and
BAL: 59  5.1% vs. 50  2.9%; 27  103 cells/mL  103 vs.
24  103 cells/mL; respectively; p < 0.05).
However, neither numbers of gd T-cells nor numbers of
other lymphocyte subsets differed significantly between
COPD smokers and COPD ex-smokers.
As shown in Fig. 4a, the relative numbers of IS gd T-cells
in COPD patients negatively correlated with pack-years of
smoking. Differently, there were no such correlations in
asthmatic patients or healthy subjects (r Z 0.147,
r Z 0.655, respectively, p > 0.05). The relative numbers
of BAL gd T-cells negatively correlated with pack-years of
smoking in COPD patients (Fig. 4b), but not in the asthma or
healthy groups (r Z 0.171, r Z 0.592, respectively,
p > 0.05). PB gd T-cells did not correlate with pack-years of
smoking in the COPD (Fig. 4c), the asthma, or control
groups (r Z 0.055, r Z 0.374, respectively, p > 0.05).
In addition, there was a positive relationship between
the percentages of IS CD8þT-cells or BAL CD8þT-cells and
pack-years of smoking in COPD group (r Z 0.500,
p Z 0.037; r Z 0.577, p Z 0.019, respectively). No rela-
tionship was found between percentage of PB CD8þT-cells
and smoking history (r Z 0.008, p Z 0.988).
Correlations between T-lymphocyte subsets in
different tissue compartments
Significant correlations between IS CD3þT-cell and BAL
CD3þT-cell counts were obtained in the COPD group,
asthmatic patients, and healthy subjects (r Z 0.655,
p < 0.001; r Z 0.551, p < 0.05; r Z 0.587, p < 0.05,
respectively). Significant correlations between percentages
of IS gd T cell and BAL gd T cells were obtained in all three
studied groups also (Fig. 5).
In COPD patients, the same as with CD3þT-cells and gd
T-cells, a significant correlation between percentages of IS
CD8þ T cells and BAL CD8þT-cells was found (r Z 0.575,
p < 0.001).
In addition to data on CD3þT cells and gd T-cells, there
was a significant correlation between percentages of IS
CD4þT-cells and BAL CD4þT-cells in asthmatic patients
(r Z 0.566, p < 0.05).
Contrarily, neither IS lymphocyte subsets nor BAL
lymphocyte subsets correlated with PB lymphocyte subsets
in any of three studied groups.
Discussion
The present study was designed to evaluate potential
differences in the distribution of T-lymphocyte subsets in
COPD and in asthma patients. The relative and absolute
values of T-lymphocyte subsets were identified. The
investigation was focused on resident T-lymphocyte subsets
in airways (IS and BAL) and on circulatory T-lymphocyte
subsets in PB, as a role T cells thought to be different in
local and systemic immune response.
Our study showed that predominant cell type in induced
sputum and bronchoalveolar lavage fluid from patients with
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Figure 4 Relationship between gd T-cells and smoking
history (by pack-years) in COPD patients. (a) The percentage of
IS gd T-cells negatively correlates with smoking pack-years
(r Z 0.642, p Z 0.002). (b) The percentage of BAL gd
T-cells negatively correlates with smoking pack-years
(r Z 0.527, p Z 0.017). (c) The percentage of PB gd T-cells
does not correlate with smoking pack-years (r Z 0.010,
p Z 0.967).
420 D. Urboniene et al.chronic obstructive pulmonary disease is CD8þT-cells and
from patients with asthma e CD4þT-cells. The main finding
of this study was that patients with COPD have reduced
relative and absolute numbers of IS gd T-cells and BAL gd T-
cells compared to asthma patients and healthy subjects. Ofimportance is that, the defined numbers of gd T-cells have
close relation with lung function decline and reverse rela-
tion with smoking (pack-years) in the patients with COPD.
Only a few studies have previously investigated the gd T-
lymphocytes in fluids obtained from the airways of COPD
patients.18,19,25 Mroz et al. investigated gd T-cells in the IS
of COPD patients and reported a lower percentage of gd T-
cells compared to patients suffering from sarcoidosis and
hypersensitivity pneumonitis. However, that study did not
compare studied patients with a group of healthy
subjects25; thus our findings herein cannot be credibly
compared with the findings of Mroz. The findings of our
study regarding the low percentage of BAL gd T-cells in
COPD patients are different compared to the results of
earliest studies.18,19 Pons et al. reported that the
percentage of BAL gd T-lymphocytes was higher in smokers
with normal lung function than in nonsmokers or COPD
patients.19 Roos-Engstrand et al. showed higher percentage
of BAL gd T-lymphocytes in smokers with normal lung
function and COPD patients compared to healthy never
smokers.18 The absence of inhaled steroids and broncho-
dilators therapy in our COPD patients may be a point of
difference with the published studies. Another important
point of difference e we did not analyze stratified patients
subgroups according to their smoking status due to small
sample size. The number of studied subjects was relatively
low due to invasive nature of BAL fluid collection e some of
subjects declined to undergo bronchoscopies. Despite these
discrepancies, it is likely that gd T-cells could be important
in preservation of normal lung function and vice versa e
lack of gd T-cells might be important in pathogenesis of
COPD.
Of importance is that, in our study, an estimate was
made of the diminution of IS gd T-cells and the corre-
sponding changes in BAL in COPD patients not only by
relative numbers, but by absolute values as well. In most
situations of clinical practice absolute values more accu-
rately depict the actual changes of T-cell subpopulations.
Distribution of gd and other T-lymphocyte subsets in COPD and asthma 421The use of relative values of analytes is common in research
practice, but has some limitation. Is the cells subpopulation
count actually increased or is the percentage skewed
because of a decrease in another subpopulation? This
question could be answered by the use of absolute values
only. So we tried to get more precise information about
actual changes of the cells by the use of absolute cell
numbers additionally to relative values. Limitation of
absolute numbers analysis e higher frequency of impreci-
sion of the results, so the analysis was done scrupulously.
In our study we did not obtain significant differences in
the gd T-cells in PB samples from COPD patients compared
to those from asthmatics and from healthy subjects.
However, Pons et al. observed significant changes of this
subpopulation in the PB of COPD patients.19 The findings of
our study regarding the decreased numbers of gd T-cells in
the IS and BAL, but not in the PB samples may indicate that
an appreciable inflammatory response with the essential
requirement of intraepithelial gd T-cells occurs in the
airway compartment locally, but not in circulation. The
known differences in phenotypes and, respectively, in
functions of pulmonary and circulatory gd T-cells13,26,27
might serve as an explanation of why the amounts of gd
T-cells in PB did not reflect the changes of the pulmonary
gd T-cell cells.
In asthma patients compared to healthy subjects no
differences were observed either in relative or in absolute
numbers of IS and BAL gd T-cells. The expansion of gd T-cells
in BAL from patients with asthma has been shown by Molfino
et al.28 and Spinozzi et al.8 Nevertheless, other investigators
did not find any differences of gd T-cells in the BAL of asth-
matics compared to healthy subjects.29 Such discrepancies
in the results could be due to the diversity of the study
population and thepossible differences in themethodologies
for the BAL analysis. The absence of uniformity in an analysis
of lymphocytes in BAL, especially by flowcytometry,30makes
comparisons between various studies quite difficult.
Previously it was reported that gd T-cells were more
prominent in the IS of patients with severe asthma.31 Patients
with acute exacerbation of asthma had an increased
percentage of gd T-cells in IS, as published by Hamzaoui
et al.17 The limited number of similar studies concerning IS gd
T-cell changes did not provide reliable data. Several studies
have determined the absolute numbers of various cells in IS
and BAL from asthma patients, but the situation with gd T-
cells is rather obscure. The results of our study showed that
there were no differences (only a tendency to differ) in the
percentage of gd T-cells between asthmatics and healthy
subjects; likewise, no differences in the number of gd T-cells
in asthma patients were determined upon exploring the
absolute counts of the cells. Small number of study patients
might serve as an explanation for the fact that our data on gd
T-lymphocytes in IS and BAL do not support a hypothesis
regarding a significance of these cells in mild to moderate
asthma. So the role of gd T-cells in chronic inflammation in
asthmatics should be ascertained in future investigations.
An analysis was also made to determine if the numbers
of gd T-cells are related to the lung function parameters in
the studied groups. In COPD patients, a lower amount of
pulmonary gd T-cells was observed in patients with the
lower FEV1 values. Our data showed that a decline of lung
function in COPD patients is related to an inadequacy ofpulmonary gd T-cells. These results support the suggestions
that gd T-cells could be relevant in tissue homeostasis e in
the protection or reparation of the lungs from injury caused
by smoking.13 A deficiency of gd T-cells may cause an
insufficient preservation of lung function. Vice versa,
a prominent upregulation of gd T-cells can warrant normal
lung function.19 Supportive data could be collected from
certain previous studies. Ekberg-Jansson et al.32 demon-
strated an increase of gd T-cells in PB and BAL from smokers
with a normal lung function. The data of Majo et al. showed
an increased percentage of gd T-cells in the lung paren-
chyma of healthy smokers.33 No relationship was found
between gd T-cells and lung function parameters in asthma
patients or in healthy subjects. Finding of normal values of
gd T-cells and the absence of their relation to lung function
let us dispute about their significance in asthma patients.
But obtained data, together with elevated numbers of
CD4þT-cells in airways of asthmatic patients, let us state
that pathogenetic mechanisms differ substantially, and the
most important lymphocytes for immune response in
asthma patients are CD4þ. Thus these results may indicate
a different inflammatory response in asthmatics compared
to the COPD patients group.
Our study showed that the numbers of CD8þT-cells in the
airways of smokers are significantly higher compared to ex-
smokers in the chronic obstructive pulmonary disease group.
A significant positive correlation was found between CD8þT-
cells and pack-years of smoking. Differences in numbers of gd
T-cells between COPD patients and the other study groups as
well as the known consideration about smoking3 as a leading
factor for developing COPD and lung function alteration
encouraged an evaluation of a possible correlation between
smoking history and gd T-cells. One of the most interesting
findings was the negative correlation of IS and BAL gd T-cells
with smoking history (by pack-years) in the COPD group but
not in the other study groups. To our knowledge, to date, no
studies haveexamined the correlation betweengdT-cells and
smoking pack-years in COPD patients. The defined reverse
relation between gd T-cells and smoking pack-years in the
COPD group permits a hypothesis that the gd T-cells (not only
the ab T-cells34) might play a significant role in the immune
response to cigarette smoking. It further suggests that
a longer smoking history and the diminution of pulmonary gd
T-cells relates to more serious lung function damage as well.
Although cigarette smoking exposure is an important deter-
minant of the development of COPD, there is significant
variability in COPD prevalence among smokers, illustrating
the role of genetic predisposition in COPD.6 Mechanisms
leading to different relation between gd T-cells and smoking
in COPD, asthma and healthy subjects are complex and could
be theoretically explained by an interaction of different
genetic, exogenous and endogenous factors. On the other
hand, intraepithelial gd T lymphocyte population is quite
heterogeneous, functionally and phenotypically.13,15 The
prevalence of different (according to their V genes rear-
rangement)gdT-cells subsets differ in healthy subjects and in
patients with pulmonary diseases.8,13,15 So, abovementioned
differences could serve as an explanation of different rela-
tions between gd T-cells and smoking in our study groups.
These findings and suggestions require further evaluation.
Whether abnormalities of T lymphocyte related immune
response represent a local inflammatory process in the
422 D. Urboniene et al.airways or reflect a systemic process is unclear. Our study
was focused to find out this. For this purpose resident T
lymphocyte subsets were analysed in different tissue
compartments: in the proximal and in the distal airways
and in blood circulation. The studies provide substantial
data that IS is derived from the proximal (large or upper)
airways, and differently, BAL e from the distal (small or
lower) airways.7,22,23,33
Previously, a significant correlation had been shown
between the number of total lymphocytes, T lymphocytes,
CD4þ lymphocytes and the CD4þ/CD8þ ratio in IS and in
BAL from patients with sarcoidosis, asthma, diffuse bron-
chiolitis or COPD.8,25,35 The comparison of cells from
different tissue compartments show a significant positive
correlation between the numbers of gd T cells from the
proximal airways and numbers of gd T cells from the distal
airways in all studied groups; the correlation between the
numbers of CD8þ T cells from the proximal and distal
airways was found only in patients with chronic obstructive
pulmonary disease and between the numbers of CD4þ T
cells e in patients with asthma. These data support the
hypothesis that T cell-mediated immune response is local
and is present throughout the bronchial tree.
Our study demonstrates a significant correlation between
the IS gd T-cells and BAL gd T-cells in the COPD group. Similar
significant correlations were observed in asthma patients and
also in healthy subjects. These results add to the data from
previous studies on the histological examination of gd T-cells
in airway cryostats; these state that gd T-cells form an inte-
gral though variablecomponent of the immunocompetent cell
population of the human airway.12 Although the relative
proportion of gd T-cells in IS and BAL samples differed and the
lymphocyte counts in ISwere lower than theywere in BAL, the
valuesof thegdT-cells significantly correlated. Thesefindings
imply that inflammatory immune response, with the
involvement of gd T-cells, is present throughout the bronchial
tree. An examination of IS gd T-cells could serve as the
groundwork for investigating chronic obstructive lung
diseases and that IS could be used as a valuable alternative to
the more conventional invasive techniques in the clinical
assessment of pulmonary diseases.25,31
The results from our study also demonstrated that the
amount of pulmonary gd T-cells did not correlate with the
quantity of circulatory gd T-cells. Previous studies identified
that gd T-cells differ according to their V genes rearrange-
ment; the major population of pulmonary gd T-cells belongs
to the V delta 1 phenotype, and the population of circulatory
gd T-cells belongs to the V delta 2 phenotype.9,15,26,27
Although much is known about the structure of gd TCR and
the distribution of the different phenotypic subsets among
various compartments of the body, less is known about their
functional role, especially in correlation with their genes
rearrangement and antigen specificity.9,15,27 The opinion is
that the different distribution and absence of correlations
between the IS or BAL and PB gd T-cells quantity may be
explained by the phenotypic and, accordingly, the functional
(in the immune response) differences of resident (pulmo-
nary) and circulatory gd T-cell populations.
In summary, according to our findings, predominant cell
type in induced sputum and bronchoalveolar lavage fluid
from patients with chronic obstructive pulmonary disease is
CD8þ T cells and from patients with asthma  CD4þ T cells.The numbers of these cells negatively correlated with lung
function parameters. Reduced amounts of gd T-cells in the
IS and BAL from COPD patients let us suggest that deficiency
of these cells may play a role in the pathogenesis of COPD.
However, it is still unclear whether decrease of gd T-cells
(with protective role in airways) is important for the
development of airway inflammation in COPD, or decrease
of these cells may be induced by the diseases (COPD) itself.
Intriguingly there are still no authoritative explanations
regarding the cause-and-effect relationship between ciga-
rette smoking and the diminution of gd T-cells.
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